m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04240)
Name
Pidilizumab
Synonyms
CT-011
    Click to Show/Hide
Status
Phase 2
TTD Drug ID
D09MRL
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Programmed cell death 1 ligand 1 (PD-L1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Pidilizumab. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Pidilizumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). [1], [2]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Pidilizumab. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Pidilizumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). [2], [3]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Pidilizumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pidilizumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). [1], [2]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Pidilizumab. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Pidilizumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). [2], [4]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Pidilizumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Pidilizumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). [1], [2]
References
Ref 1 Correlation of m6A methylation with immune infiltrates and poor prognosis in non-small cell lung cancer via a comprehensive analysis of RNA expression profiles. Ann Transl Med. 2021 Sep;9(18):1465. doi: 10.21037/atm-21-4248.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N(6)-methyladenosine modification of PD-L1 mRNA in breast cancer. Mol Cancer. 2022 Feb 23;21(1):60. doi: 10.1186/s12943-021-01447-y.
Ref 4 M(6)A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma. Cancer Res. 2021 Sep 15;81(18):4778-4793. doi: 10.1158/0008-5472.CAN-21-0468. Epub 2021 Jul 23.